Author:
Zhang Leisheng,Yang Xiaonan,Han Zhihai,Han Zhongchao,Guo Tiankang,Gao Xiaowei,Cai Hui
Abstract
Longitudinal studies have indicated the multifaceted regimens for atopic dermatitis (AD) administration, including ultraviolet phototherapy, oral JAK inhibitors, and the concomitant adjunctive therapies according to the American Academy of Dermatology published Guidelines of Care for the Management of Atopic Dermatitis. As a disease with typical characteristics of relapsing pruritus and chronic inflammation, AD has caused heavy burden on children and adults, as well as healthcare providers and family members. As a multi-factorial disease, AD has been considered primarily derived by Th2 dysfunction, with clinical and molecular heterogeneity. The current therapeutic regimens are various and largely due to the diversity in the wide spectrum of the clinical phenotypes based on epidermal barrier disruption, genetic predisposition, and dysregulation of patients’ immune system. Meanwhile there’s an urgent need for developing safer and long-term agents to efficiently control moderate to severe AD. In this book chapter, we mainly summarized the fundamental concept, clinical manifestation, pathophysiology and molecular mechanisms of AD, and in particular, the biofunction and modulation of natural killer (NK) cells for AD. Collectively, the contents in this chapter will help further understand the landscape of this disease and the rationale behind new emerging therapies.
Reference60 articles.
1. Hassan S, Hamideh N, Poulos C, Cheema S, Rangwani S, Lio PA. Atopic dermatitis biomarkers and the movement toward personalized treatment. Dermatitis. 2021;(1S):S8-S14
2. Jurakic Toncic R, Marinovic B. The role of impaired epidermal barrier function in atopic dermatitis. Acta Dermatovenerologica Croatica. 2016;(2):95-109
3. Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. The Journal of Clinical Investigation. 2012;(2):440-447
4. Yue H, Umehara Y, Trujillo-Paez JV, Peng G, Nguyen HLT, Chieosilapatham P, et al. Exogenous factors in the pathogenesis of atopic dermatitis: Irritants and cutaneous infections. Clinical and Experimental Allergy. 2021;(3):382-392
5. Kraft MT, Prince BT. Atopic dermatitis is a barrier issue, not an allergy issue. Immunology and Allergy Clinics of North America. 2019;(4):507-519